In summary, we report on the rational combination of nanosonosensitiser-augmented SDT and anti-PD-L1 checkpoint blockade-enabled immunotherapy for highly efficient tumour therapy, which is based on the construction of a multifunctional nanosonosensitiser (HMME/R837@Lip) with the encapsulated sonosensitisers and immune adjuvant. This evidence concerns the gene CD274 and neoplasm.